ABOUT BICYCLE THERAPEUTICS

Bicycle Therapeutics is pioneering first in class therapeutics to treat cancer and other debilitating diseases based on its proprietary bicyclic peptides (Bicycles®) platform. Bicycles are a breakthrough new therapeutic class that combine antibody-like affinity and selectivity with small molecule-like tissue penetration, tuneable exposure, flexible pharmacokinetics and chemical synthesis. Bicycle Therapeutics is rapidly advancing towards the clinic in collaboration with Cancer Research UK (CRUK), with its lead programme using a Bicycle Drug Conjugate® to selectively deliver toxin to tumours. Bicycle is also exploring the potential of bicyclic peptides as targeted, titratable and rapidly penetrant immunomodulators, overcoming the challenges seen for other agents with long exposure, irreversible effects and attendant toxicities. The company is collaborating in oncology, as evidenced by the recently announced CRUK partnership, and in other areas, such as respiratory and cardiovascular and metabolic disease, through a significant new partnership with AstraZeneca, to realise the full therapeutic potential of the Bicycle technology.

Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the Medical Research Council Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company: Sir Greg Winter, a pioneer in monoclonal antibody development, and Professor Christian Heinis, an accomplished researcher in the field of peptide therapeutics. This technology allows phage presentation of linear Bicycle precursor peptides, followed by an on-phage chemical cyclisation to generate enormously diverse (>1015 variants), structurally constrained, Bicycle libraries. These libraries, which can be varied by loop size, symmetry and scaffolding agent, can then be screened against almost any soluble or cell based target using the proprietary Bicycle screening process. Bicycle Therapeutics is headquartered in Cambridge, U.K. and has U.S. operations in Cambridge, Massachusetts.

Bicycle Therapeutics is backed by a top-tier investor syndicate and closed a $32 million Series A funding round in October 2014 as well as a $52 million Series B funding round in June 2017.

 
 

LEADERSHIP

Kevin Lee, Ph.D., MBA (CEO)

Kevin Lee, Ph.D., MBA, is Chief Executive Officer of Bicycle Therapeutics. Under his leadership, Bicycle Therapeutics’ strategy has become focused on developing novel treatments for oncology using Bicycle Drug Conjugates® to selectively deliver toxins and other payloads to tumours. Dr. Lee joined Bicycle Therapeutics from Pfizer, where he served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programmes across the full spectrum of research and development, established Pfizer’s Rare Disease strategy, conceptualized and implemented the company’s Gene Therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GSK and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, Dr. Lee lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.

Dr. Lee studied Pharmaceutical Sciences at Nottingham University followed by a Ph.D. in Pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Dr. Lee is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick. Dr Lee is also the industry representative on the National Institute for Health Research (NIHR) Rare Disease translational research committee (TRC).

 

Ros Deegan, MBA (President and CBO, Bicycle Therapeutics Inc.)

Ros Deegan, MBA, is President and Chief Business Officer of Bicycle Therapeutics Inc., the U.S. subsidiary of Bicycle Therapeutics. Prior to joining Bicycle, Ms. Deegan most recently served on the senior leadership team at Trevena, Inc. as Senior Vice President, Business Development and Operations and previously held the role of Head of Finance and Operations. While at Trevena, she was responsible for start-up operations, negotiating a significant option and license agreement with Forest Laboratories, Inc., and leading finance and human resources through to the company’s first S-1 filing with the Securities and Exchange Commission. During her tenure, the company moved three programmes into the clinic, and raised over $200 million in private and public financings. Prior to joining Trevena, Ms. Deegan served as Director of Business Development at GSK in the U.S., leading transactions for the virtual immuno-inflammation group. Prior to that, she served as the Director of Operations for the Centre of Excellence for External Drug Discovery (CEEDD) and as Marketing Manager for GSK’s U.K. launch of Bonviva for post-menopausal osteoporosis and in Business Development.

Ms. Deegan holds a first-class degree from Cambridge University and received her MBA with distinction from INSEAD.

 

Nick Keen, Ph.D. (Chief Scientific Officer)

Nick Keen, Ph.D., is Chief Scientific Officer of Bicycle Therapeutics. He joined Bicycle from Novartis, where for the past five years he served as the Cambridge (US) head of oncology research. During his tenure at Novartis, Dr. Keen was responsible for leading research from basic target identification and drug discovery through to enabling early clinical trials. Under his leadership, the group delivered multiple new therapies to the clinic spanning the range from novel allosteric small molecule inhibitors of previously intractable targets, to advanced biologic therapies. His team was also responsible for publishing many basic discoveries in cancer biology, and for building industry leading platforms in whole genome scale target identification and in modelling the diversity of human clinical trials in mice.

Prior to his time at Novartis, Dr. Keen led the early lead generation group for oncology at AstraZeneca’s US research site with a particular focus on epigenetic regulation, and before this held positions of increasing responsibility in AstraZeneca’s UK oncology research group. During his time at AstraZeneca he delivered multiple agents to the clinic and was instrumental in the acquisition of KuDOS Pharmaceuticals leading to the registration of Olaparib (a first in class PARP inhibitor) for the treatment of BRCA mutant cancers.

Dr. Keen was an undergraduate at the University of Cambridge where he studied Natural Sciences, a graduate student with the ICRF in Cambridge and completed his post-doctoral studies at the Laboratory of Molecular Biology in Cambridge.

 
Maria headshot for bicycle site.jpg

Maria Koehler, M.D., Ph.D. (Chief Medical Officer)

Maria Koehler, M.D., Ph.D., is Chief Medical Officer of Bicycle Therapeutics. She joined Bicycle from Pfizer, where she was Vice President of Strategy, Innovation and Collaborations for the Oncology Business Unit. At Pfizer, Dr. Koehler was a key member of the oncology leadership team responsible for creating and coordinating innovative strategies to bring cancer therapeutics from early-stage clinical trials to use on hospital floors around the world. Her accomplishments at Pfizer include leading development strategies for Palbociclib/IBRANCE, which was launched in 2015, and shaping the oncology portfolio.

Prior to joining Pfizer, Dr. Koehler was the Group Leader for the Medicine Development Center of GlaxoSmithKline Oncology, and a Senior Medical Director for Oncology Research and Development at AstraZeneca. During her academic career, she was the Clinical Director of Bone Marrow Transplantation at University Hospital in Pittsburgh, PA, and Director of the Bone Marrow Transplant Program and Associate Professor at St.Christopher’s Hospital in Philadelphia, PA. She is a Board Certified Hematology/Oncology physician, and the author of more than 160 peer reviewed publications and book chapters. Dr. Koehler received her M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.

 
DSC_6788.JPG

Lee Kalowski, MBA (CFO)

Lee Kalowski is Chief Financial Officer of Bicycle Therapeutics. Prior to joining Bicycle, Mr. Kalowski served as the Chief Financial Officer of Tokai Pharmaceuticals, Inc., where he helped lead the company’s $105 million initial public offering in 2014. Previously, he was vice president, global biotechnology equity research at Credit Suisse, where he served as a senior research analyst covering the biotechnology sector. Before that, he worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group.

Mr. Kalowski received a B.A. in biology and economics from Union College and an MBA from The Wharton School of the University of Pennsylvania.

 

Michael Skynner, Ph.D. (VP Operations)

Michael Skynner, Ph.D., is Vice President of Operations at Bicycle Therapeutics. He joined Bicycle Therapeutics from Pfizer where he led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium (RDC). The RDC was an innovative agreement between Pfizer and 20 leading U.K. universities that created research partnerships between Pfizer, academic researchers and patient groups to develop new therapies for rare and orphan diseases using a new collaborative paradigm. As part of those activities he also established Pfizer’s Genetic Medicine Institute, a bespoke research unit in central London embedded within the U.K. gene therapy academic community. Previously, he established a Discovery Performance Unit at GSK focused on developing therapeutics targeting inflammatory kinases using an externalised and partnered model with leading European biotechnology companies. In his time at GSK he successfully advanced multiple molecules from screening into clinical trials. Prior to GSK he co-founded a successful biotech start-up company, Cambridge Biotechnology Ltd (CBT), which specialised in developing small molecule and peptide therapeutics for inflammation and metabolic disease. CBT was sold to Swedish Orphan Biovitrum.

Dr. Skynner obtained his Ph.D. in Biochemistry at Imperial College and is an author on over 30 peer-reviewed scientific publications.

 

 

Gillian Langford, Ph.D. (VP Clinical and Therapeutics)

Gillian Langford, Ph.D, is Vice President of Clinical and Therapeutics at Bicycle Therapeutics and has over 20 years of drug development experience in both the pharmaceutical and biotechnology sectors.  Dr. Langford joined Bicycle from Boyd Consultants, where she was Director of Programme Management, and was involved in working with European and North American companies developing oncology products and gene based medicines.  Prior to joining Boyd Consultants, she worked at Alizyme Therapeutics and Ark Therapeutics where she was responsible for all aspects of the company’s lead gene therapy product, including non-clinical studies, manufacturing, regulatory and clinical trials (Phase 2 and 3).  Dr. Langford was also employed by Imutran Ltd, a Novartis Pharma AG company, working in the field of xenotransplantation, initially as Unit Head of Molecular Biology and subsequently as Unit Head of Retroviral research where she was responsible for internal research projects and collaborations with academic groups.


Dr Langford graduated from Imperial College and obtained her Ph.D. in molecular biology at York University and is an author on over 35 scientific publications.

 

Peter U. Park, Ph.D. (VP Oncology)

Peter Park, Ph.D., is Vice President of Oncology Research at Bicycle Therapeutics Inc. Dr. Park brings over 14 years of oncology drug discovery experience in antibody and antibody-drug conjugate (ADC) therapeutics.  Previously, he was Vice President of Biology at Mersana Therapeutics, Inc., where he co-invented and oversaw the discovery and development of novel Fleximer-based ADC, XMT-1522 and XMT-1536. He also led the joint research steering committee for the collaboration with Merck KgGA. Prior to that, Dr. Park served at ImmunoGen, Inc. in various roles, most recently as Senior Director of Discovery Research. In this role, he managed the discovery research portfolio for the development of novel monoclonal antibody and ADCs for the internal pipeline and for partners.  He oversaw three departments that included Discovery Research, Antibody Engineering and Cell Line Development. At ImmunoGen, Dr. Park co-invented and advanced many clinical candidates, including Isatuximab (SAR650984), which was licensed to Sanofi and is currently in Phase 3 testing for multiple myeloma.


Dr. Park received his Ph.D. and B.S. in Biology from Massachusetts Institute of Technology. 

Board of Directors

Stephen Hoffman, M.D., Ph.D. (Chairman)

Stephen Hoffman M.D., Ph.D., is President of the consulting firm 10x Capital, Inc. and has been a Senior Advisor to PDL BioPharma, Inc. since February 2014. Prior to that he served as a Managing Director at Skyline Ventures, a venture capital firm, from 2007 to 2014 and was general partner at TVM Capital from 2003 to 2007. Prior to TVM, he served as President, Chief Executive Officer and a Director of Allos Therapeutics from 1994 to 2002, where he remained as Chairman until its acquisition by Spectrum Pharmaceuticals, Inc. in 2012. Allos in-licensed PDX from Memorial Sloan-Kettering Cancer Center, the Southern Research Institute and SRI International in 2002 and received U.S. Food and Drug Administration approval for Folotyn in 2009 for the treatment of the orphan disease peripheral T-cell lymphoma. Allos successfully launched and commercialized Folotyn in the U.S., and licensed it to Mundipharma for commercialization in ex-U.S. territories. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that was acquired by Baxter International, Inc. in 1998, where he held the position of Vice President of Science and Technology from 1987 until 1990. He currently serves on the board of directors of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Genocea Biosciences, Inc. (NASDAQ: GNCA) and Hovione, Ltd.

Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology (1990 to 1994), both at the University of Colorado, and holds a Ph.D. in bio-organic chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine. He is also board-certified in Dermatology.

 

Kevin Lee, Ph.D., MBA (CEO)

Kevin Lee, Ph.D., MBA, is Chief Executive Officer of Bicycle Therapeutics. Under his leadership, Bicycle Therapeutics’ strategy has become focused on developing novel treatments for oncology using Bicycle Drug Conjugates® to selectively deliver toxins and other payloads to tumours. Dr. Lee joined Bicycle Therapeutics from Pfizer, where he served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programmes across the full spectrum of research and development, established Pfizer’s Rare Disease strategy, conceptualized and implemented the company’s Gene Therapy strategy with the creation of the Genetic Medicine Institute and also founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GSK and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, Dr. Lee lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.

Dr. Lee studied Pharmaceutical Sciences at Nottingham University followed by a Ph.D. in Pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Dr. Lee is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick. Dr Lee is also the industry representative on the National Institute for Health Research (NIHR) Rare Disease translational research committee (TRC).

 

Rich Aldrich, MBA (Observer)

Rich Aldrich, MBA, is a co-founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Vertex Pharmaceuticals (NASDAQ: VRTX), Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by Glaxo in 2008), Concert Pharmaceuticals (NASDAQ: CNCE), where he serves as Chairman of the Board, and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), OvaScience (NASDAQ: OVAS), Verastem (NASDAQ: VSTM) and Axial Biotherapeutics.  Mr. Aldrich also serves as Chairman of the Board of Directors at Longwood portfolio company KalVista Pharmaceuticals and is a Director of Longwood portfolio companies Mitobridge, Inc., Colorescience, Inc. and Renovia, Inc. Prior to co-founding Longwood, Mr. Aldrich was General Partner of RA Capital, a biotechnology investment fund he co-founded in 2001. Mr. Aldrich was a founding employee of Vertex where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.

 

Michael Anstey, DPhil (Director)

Michael Anstey, DPhil, is an Investment Director at Cambridge Innovation Capital (CIC), specialising in healthcare investments. Before joining CIC, Dr. Anstey was a Principal in the Healthcare Practice of the Boston Consulting Group (BCG), where he advised biopharma companies across North America, Europe, and Asia on a range of topics, including commercial strategy, corporate development, R&D, and medical affairs. Prior to BCG, Dr. Anstey was on the Investment Team at Oxford Capital Partners. He is also a co-founder of Proteorex Therapeutics, a Canadian biotechnology company.  Dr. Anstey graduated with a 1st Class Honors degree in Biology from Queen’s University, Canada and earned his DPhil in Zoology in the field of neurobiology from Oxford University.

 

 

Kate Bingham, MBA (Director)

Kate Bingham, MBA, joined SVLS in 1991. She currently serves or has served on the boards of companies in the U.K., U.S., Ireland, Sweden and Germany. She has been responsible for past investments in Alantos, Auxilium, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed and RespiVert. Current investments include Autifony, Bicycle Therapeutics, Convergence and TopiVert.

Prior to joining SVLS, Ms. Bingham worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge (U.S.) and at Monitor Company, a strategy consulting firm. She has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA.

 

Deborah Harland, Ph.D., MBA (Director)

Deborah Harland, Ph.D., MBA, joined SR One in 2005 to establish the firm’s European investment office. She brings to SR One extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 20-year tenure in the pharmaceutical industry. She is currently a member of the board of directors of Mission Therapeutics Limited, Protaffin AG, Bicycle Therapeutics Limited, Syntaxin Limited, and F-star GmbH. She was previously a member of the board of directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007) and Pharmakodex Limited (sold to Orexo) and an observer on the boards of Ablynx (IPO, Euronext Brussels 2007) and 7TM Pharma. Dr. Harland received her B.Sc. (Hons.) in Pharmacology from the University of Bath, her Ph.D. in Pharmacology from the University of London and her MBA from Henley Management College.    

 

Anja König, Ph.D. (Director)

Anja König, Ph.D., is a Managing Director at the Novartis Venture Fund in the Basel office. She is active in Europe and the U.S. She serves on the board of directors for Nabriva, Heptares, Covagen, F2G and Bicycle Therapeutics. Prior to joining Novartis, she was an Associate Partner at McKinsey and Company, a global consultancy, in New York City where she was a leader in McKinsey's North American Pharmaceutical Practice and a knowledge expert on pharmaceutical research and drug discovery.

Dr. König is a scientist by training and holds a Ph.D. in Physics from Cornell University.

   

 

Jason Rhodes, MBA (Director) 

Jason Rhodes is a Partner at Atlas Venture and focuses on the creation, development and business strategy of novel therapeutics companies. He is a founder and the chairman and acting CEO of Disarm Therapeutics and Torus Therapeutics and is a member of the board of directors of Replimune, Gemini Therapeutics, Accent Therapeutics, and Bicycle Therapeutics. Prior to joining Atlas in 2014, Jason was President and Chief Financial Officer of Epizyme, Inc. (NASDAQ: EPZM), a public biopharmaceutical company. Prior to Epizyme, Jason led business development at Alnylam (NASDAQ: ALNY). Prior to Alnylam, Jason was a founder and partner with Fidelity Biosciences (now F-Prime Capital Partners), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), Tetraphase (NASDAQ: TTPH) and Mersana (NASDAQ: MRSN). He holds a BA from Yale University and an MBA from the Wharton School of the University of Pennsylvania.

   

 

James Lee (Director)

James is a Managing Director at Vertex Holdings and Vertex Ventures HC.   Vertex Ventures HC invests in global lifescience and healthcare opportunities, primarily focusing on therapeutic medical devices and biopharma sectors.  Vertex Ventures HC is part of a global venture fund network under the auspices of Vertex Holdings, a member of Temasek Holdings.  

James serves on the board of directors for Holaira, Palleon Pharma and Bicycle Therapeutics.

Prior to Vertex, James served as Managing Director at Roots Capital, a multi-family office in Singapore;  General Manager at Fullerton Credit Services, a China-based financial services firm wholly-owned by Temasek; and a naval officer in the Singapore Armed Forces.

James graduated from Oxford University with a Masters and First Class Honours in Engineering Science.

 

Sir Gregory Winter, FRS (Co-founder and Director)

Professor Sir Gregory Winter is a member of the Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge, U.K., and has served as both Deputy and Acting Director. He is a Fellow of the Royal Society, was knighted in 2004 for services to science and in 2012 was appointed by the Queen as Master of Trinity College, Cambridge.

He invented techniques to humanise rodent antibodies for use as therapeutics, and co-developed alemtuzumab/Campath-1H. Later, he developed methods to make fully human antibodies against human self-antigens using antibody libraries. His inventions are used in most of the antibody products on the market, including the humanised antibodies alemtuzumab/Campath-1H, trastuzumab/Herceptin, bevacizumab/Avastin, palivizumab/Synagis and the first human antibody (adalimumab/Humira) to be approved by the U.S. Food and Drug Administration.

Sir Gregory has acted as an entrepreneur to translate his scientific inventions to medicines. He was a founder of Cambridge Antibody Technology (CAT, 1989) and Domantis (2000); these companies pioneered the use of antibody libraries to make fully human antibody therapeutics including adalimumab/Humira and belimumab/Benlysta.

Sir Gregory has won several international scientific prizes, including the Prix Louis Jeantet de Medecine (Switzerland) in 1989; the King Faisal International Prize for Medicine (Molecular Immunology, Saudi Arabia) in 1995; the Biochemical Analysis Prize of the German Society for Clinical Chemistry in 1995; the Cancer Research Institute William B. Coley Award (U.S.) in 1999; and the Royal Medal of the Royal Society in 2011. For his work with industry, he received the National Biotechnology Ventures Award (US) in 2004 and the BioIndustry Association Award (UK) in 2008. In March 2013 he was awarded the Gairdner Prize for the engineering of humanised monoclonal antibodies and their widespread use in medical therapy, particularly for treatment of cancer and immune disorders.

Sir Gregory is a graduate of University of Cambridge (1973), specialising in chemistry and biochemistry; for his Ph.D. (1976) and postdoctoral work (1977-1981) he specialised in protein and nucleic acid sequencing, respectively, and with colleagues determined the genome sequence of influenza virus. From 1982 he pioneered the science of protein engineering, focusing first on enzymes (with A. Fersht) and then antibodies.

Investors